AstraZeneca Deploys High-Sensitivity Troponin Test As Brilinta Biomarker

In PLATO post hoc analysis, researchers correlate results on new, more sensitive heart damage test from Roche with positive outcomes for Brilinta in preventing events in patients who are managed medically as well as invasively.